TELA Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on June 9, 2026, specifically the 2026 Annual Meeting of Stockholders for TELA Bio, Inc. The meeting was conducted virtually. As of the record date (April 24, 2026), there were 44,765,928 outstanding shares of common stock.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance actions and voting results.
Material Changes and Voting Results
Stockholders approved four key proposals at the Annual Meeting:
- Director Elections: Joseph Capper, Betty Jo Rocchio, and William Plovanic were elected as Class I directors to serve until the 2029 Annual Meeting. All three received significant "For" votes (ranging from approximately 27.2 million to 27.6 million).
- Accountant Ratification: KPMG LLP was ratified as the independent registered public accounting firm for the 2026 fiscal year with 33,443,686 votes in favor.
- Executive Compensation: Stockholders approved, on a non-binding advisory basis, the compensation of named executive officers. The proposal passed with 20,891,695 votes for, though it faced notable opposition with 6,900,032 votes against.
- Equity Plan Amendment: Stockholders approved an amendment to the Amended and Restated 2019 Equity Incentive Plan to increase the authorized shares issuable by 3,500,000 shares. The amendment became effective immediately upon approval.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future financial guidance, operational outlook, or specific risk factors. The document references the Definitive Proxy Statement filed on April 30, 2026, for a detailed description of the Plan Amendment terms.
Investor Verification Checklist
- Verify the impact of the 3,500,000 share increase on potential dilution by reviewing the full text of the Plan Amendment (Exhibit 10.1).
- Review the April 30, 2026 Proxy Statement for detailed terms of the equity plan and executive compensation rationale.
- Monitor the company's upcoming financial reports for updates on cash burn and liquidity, as this 8-K does not contain financial statements.
- Confirm the tenure of the newly elected directors (Joseph Capper, Betty Jo Rocchio, William Plovanic) through the 2029 Annual Meeting.